Yunkang Group Posts RMB601 Million Revenue and Expands Scope 3 Carbon Accounting in 2025 ESG Report

Yunkang Group released its fourth Environmental, Social and Governance (ESG) Report, detailing 2025 performance across governance, operations, environment and social impact. For 2025, the company generated RMB601 million in revenue and closed the year with total assets of RMB2.74 billion.

Governance metrics show an independent director ratio above 40 %, a female director proportion of 14.3 % and no corruption litigation. The Guangzhou Medical Laboratory achieved ISO 37301 compliance, ISO 14001 environmental and ISO 45001 occupational-health certifications, while the group’s overall ESG score in S&P Global’s Corporate Sustainability Assessment rose to 48.

Operationally, Yunkang’s testing and pathology network served more than 1,500 medical institution-alliance clients and nearly 450 joint-construction hospitals nationwide. The group launched the “Zhi Yun” medical large language model, upgraded three core digital platforms (“Zhi Yun”, “Xin Yun”, “Teng Yun”) and deployed AI Pathology Platform 2.0, which doubled per-capita slide-reading efficiency.

Environmental data show total energy consumption of 4.81 million kWh and an intensity of 8.00 thousand kWh per million renminbi of revenue. Total greenhouse-gas emissions reached 9,611.57 tCO₂e, or 15.99 tCO₂e per million renminbi, after the company extended its inventory to include key Scope 3 categories for the first time. New-energy vehicles accounted for about 70 % of its nationwide cold-chain fleet, and on-site photovoltaic panels supplied a portion of laboratory power demand.

On the social front, women represented 57.24 % of the workforce and 35.42 % of management. The group recorded zero work-related fatalities, delivered 11,809 hours of employee training and logged 24,400 learning participations via its “Fu Yun” platform. Community initiatives included 245 charitable diagnostic events and more than 25,600 complimentary medical examinations, benefiting over 14,700 individuals.

Yunkang’s 2025 ESG agenda remains anchored on lean operations, data-driven healthcare innovation and the national “dual-carbon” strategy, with continued emphasis on transparency, integrity and inclusive health services.